BPG is committed to discovery and dissemination of knowledge
Opinion Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. May 26, 2026; 18(5): 119394
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.119394
When the liver hardens the heart: Valvular calcification as an emerging cardiohepatic phenotype in cirrhosis
Yasser Fouad, Amr Abdel Zaher Shehata
Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine Minia University, Minia 19111, Egypt
Amr Abdel Zaher Shehata, Department of Cardiology, Minia University, Minia 19111, Egypt
Author contributions: Fouad Y and Shehata AAZ conceptualized the letter, wrote, revised and approved the final version of the manuscript.
Conflict-of-interest statement: Both authors declared no conflict of interest.
Corresponding author: Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine Minia University, Al Horryia Street, Minia 19111, Egypt. yasserfouad10@yahoo.com
Received: January 26, 2026
Revised: March 1, 2026
Accepted: April 3, 2026
Published online: May 26, 2026
Processing time: 113 Days and 10.7 Hours
Abstract

Although valvular calcification is still a little-known aspect of cardiohepatic interactions, cardiovascular disease has become a significant predictor of outcomes in patients with liver cirrhosis. Some studies present significant evidence that cirrhosis of any cause strongly predicts mitral annular calcification, while cirrhosis, especially of fatty aetiology, is independently associated with aortic valve calcification. These correlations show a clear liver-driven pro-calcific phenotype, even though cirrhotic patients have a lower burden of conventional cardiovascular risk factors than matched cardiovascular controls. Researchers advance the field from descriptive associations to clinically meaningful risk stratification by combining robust multivariable modelling with pragmatic echocardiographic calcium scoring. Their results highlight the need for integrated hepatology–cardiology approaches and challenge conventional views of cardiovascular risk in cirrhosis. It is important to acknowledge valve calcification as a structural sign of systemic liver disease, which may have consequences for long-term cardiovascular care, transplant evaluation, and surveillance.

Keywords: Cirrhosis; Cardiohepatic interaction; Valvular calcification; Metabolic dysfunction; Fatty liver; Risk stratification

Core Tip: One new but little-known aspect of cardiohepatic disease is valve calcification. Cirrhosis of any aetiology strongly predicts mitral annular calcification, even in the presence of fewer conventional cardiovascular risk factors, whereas fatty liver-related cirrhosis is independently linked to aortic valve calcification. These results imply that a unique pro-calcific cardiovascular phenotype caused by hepatic and metabolic dysfunction is promoted by cirrhosis. Regular evaluation of cirrhosis and transplants should include echocardiographic assessment of valvular calcification to enhance cardiovascular risk stratification and facilitate early, multidisciplinary intervention.

Write to the Help Desk